References
- Chow, S.-C., Liu, J. P. (2008). Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd. Boca Raton, FL: Chapman & Hall/CRC Biostatistics Series.
- Dranitsaris, G., Dorward, K., Hatzimichael, E., Amir, E. (2013). Clinical trial design in biosimilar drug development. Investigational New Drugs 31:479–487.
- European Medicines Agency. (2014). Guideline on Similar Biological Medicinal Products. London, UK: CHMP. Report No. CHMP/437/04 rev 1.
- Noaiseh, G., Moreland, L. (2013). Current and future biosimilars: Potential practical applications in rheumatology. Dove Medical Press 3:27–33.
- Tsong, Y., Dong, X., Shen, M. (2017). Development of statistical methods for analytical similarity assessment. Journal of Biopharmaceutical Statistics 27(2):192–205.
- US Food and Drug Administration (2015a). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), Rockville, MD.
- US Food and Drug Administration (2015b). Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product: Guidance for industry. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), Rockville, MD.
- US Food and Drug Administration. (2015c). Biosimilars: Questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Silver Spring, MD: U.S. Food and Drug Administration.
- US Food and Drug Administration (2016a). Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), Rockville, MD.
- US Food and Drug Administration. (2016b). Arthritis Advisory Committee Meeting Briefing Book for BLA 761024. Silver Spring, MD: U.S. Food and Drug Administration.
- Ventola, C. L. (2013). Biosimilars: Part 1: Proposed regulatory criteria for FDA approval. Pharmacy and Therapeutics 38:270–287.
- Yoo, D. H., Suh, C.-H., Shim, S. C., et al. (2017). A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 76:566–570.